Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 16 studies | 32% ± 16% | |
type II pneumocyte | 10 studies | 33% ± 9% | |
type I pneumocyte | 8 studies | 30% ± 6% | |
epithelial cell | 8 studies | 31% ± 16% | |
basal cell | 6 studies | 19% ± 4% | |
secretory cell | 5 studies | 18% ± 2% | |
club cell | 4 studies | 34% ± 10% | |
monocyte | 4 studies | 27% ± 13% | |
mesothelial cell | 3 studies | 22% ± 3% | |
luminal cell of prostate epithelium | 3 studies | 28% ± 2% | |
GABAergic neuron | 3 studies | 20% ± 3% | |
glutamatergic neuron | 3 studies | 26% ± 4% | |
alveolar macrophage | 3 studies | 28% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 5 studies | 20% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2913.86 | 1445 / 1445 | 97% | 21.11 | 178 / 183 |
prostate | 98% | 1122.25 | 241 / 245 | 96% | 17.98 | 481 / 502 |
stomach | 100% | 1707.33 | 359 / 359 | 91% | 14.94 | 260 / 286 |
pancreas | 98% | 872.95 | 320 / 328 | 93% | 21.19 | 166 / 178 |
lung | 100% | 2867.01 | 577 / 578 | 90% | 20.41 | 1036 / 1155 |
kidney | 99% | 1147.26 | 88 / 89 | 90% | 17.50 | 815 / 901 |
intestine | 99% | 2178.13 | 960 / 966 | 90% | 14.12 | 474 / 527 |
thymus | 100% | 2076.00 | 653 / 653 | 88% | 34.99 | 532 / 605 |
uterus | 99% | 1654.07 | 169 / 170 | 83% | 11.47 | 383 / 459 |
bladder | 100% | 1652.90 | 21 / 21 | 73% | 9.38 | 367 / 504 |
breast | 96% | 725.14 | 439 / 459 | 73% | 8.76 | 811 / 1118 |
liver | 99% | 1172.45 | 224 / 226 | 47% | 4.39 | 191 / 406 |
skin | 99% | 1514.83 | 1797 / 1809 | 25% | 1.85 | 118 / 472 |
ovary | 27% | 157.86 | 49 / 180 | 91% | 10.62 | 390 / 430 |
adrenal gland | 85% | 594.05 | 220 / 258 | 14% | 1.04 | 33 / 230 |
blood vessel | 99% | 1248.26 | 1326 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1256.50 | 1186 / 1204 | 0% | 0 | 0 / 0 |
heart | 92% | 1097.03 | 790 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 71% | 6.95 | 32 / 45 |
brain | 44% | 280.49 | 1166 / 2642 | 5% | 0.43 | 38 / 705 |
peripheral blood | 41% | 506.98 | 383 / 929 | 0% | 0 | 0 / 0 |
muscle | 36% | 250.28 | 293 / 803 | 0% | 0 | 0 / 0 |
spleen | 27% | 124.12 | 66 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0030500 | Biological process | regulation of bone mineralization |
GO_0006686 | Biological process | sphingomyelin biosynthetic process |
GO_1905373 | Biological process | ceramide phosphoethanolamine biosynthetic process |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0047493 | Molecular function | ceramide cholinephosphotransferase activity |
GO_0002950 | Molecular function | ceramide phosphoethanolamine synthase activity |
GO_0033188 | Molecular function | sphingomyelin synthase activity |
GO_0005515 | Molecular function | protein binding |
GO_0016301 | Molecular function | kinase activity |
Gene name | SGMS2 |
Protein name | Phosphatidylcholine:ceramide cholinephosphotransferase 2 (EC 2.7.8.27) (Sphingomyelin synthase 2) Sphingomyelin synthase 2 |
Synonyms | SMS2 |
Description | FUNCTION: Sphingomyelin synthase that primarily contributes to sphingomyelin synthesis and homeostasis at the plasma membrane. Catalyzes the reversible transfer of phosphocholine moiety in sphingomyelin biosynthesis: in the forward reaction transfers phosphocholine head group of phosphatidylcholine (PC) on to ceramide (CER) to form ceramide phosphocholine (sphingomyelin, SM) and diacylglycerol (DAG) as by-product, and in the reverse reaction transfers phosphocholine from SM to DAG to form PC and CER. The direction of the reaction appears to depend on the levels of CER and DAG in the plasma membrane . Does not use free phosphorylcholine or CDP-choline as donors . Can also transfer phosphoethanolamine head group of phosphatidylethanolamine (PE) on to ceramide (CER) to form ceramide phosphoethanolamine (CPE) . Regulates receptor-mediated signal transduction via mitogenic DAG and proapoptotic CER, as well as via SM, a structural component of membrane rafts that serve as platforms for signal transduction and protein sorting . To a lesser extent, plays a role in secretory transport via regulation of DAG pool at the Golgi apparatus and its downstream effects on PRKD1 . Required for normal bone matrix mineralization . . |
Accessions | ENST00000394686.3 ENST00000359079.8 E5RJ63 ENST00000503862.5 Q8NHU3 ENST00000690982.1 ENST00000506993.1 E5RGG5 ENST00000503385.1 E5RJU3 ENST00000394684.8 |